NCT00111189View on ClinicalTrials.gov

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 29, 2008

Conditions
Schizophrenia
Interventions
DRUG

Placebo

Placebo every 4 wk up to 24 mo

DRUG

Paliperidone Palmitate

25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo

Trial Locations (55)

Unknown

Little Rock

Cerritos

Santa Ana

Hialeah

Chicago

Granite City

Lake Charles

Shreveport

Flowood

St Louis

Clementon

Cedarhurst

Cleveland

Oklahoma City

Conroe

DeSoto

Irving

San Antonio

Costa Rica

Mexico City

Mérida

Monterrey

Bucharest

Cluj-Napoca

Iași

Sibiu

Tg Mures

Timișoara

Arkhangelsk

Moscow

Moscow Russia

Saint Petersburg

Samara

Yaroslavl

Cape Town

Centurion Gauteng

Florida Johannesburg Gauteng

Johannesburg

Gwangju

Inchun

Pusan

Seoul

Changhua

Kaohsiung City

Tainan City

Taoyuan District

Dnipro

Hlevakha

Kharkiv

Kiev

Kyiv

Lviv

Odesa

Simferopol

Vinnitsa

Sponsors
All Listed Sponsors
collaborator

Janssen-Cilag International NV

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY